• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2012 Product Image

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2012

  • ID: 2366429
  • December 2012
  • 108 Pages
  • Global Markets Direct

FEATURED COMPANIES

  • A.P. Pharma, Inc.
  • Acacia Pharma Ltd.
  • AGI Therapeutics plc
  • Almac Discovery Ltd.
  • Aphios Corporation
  • Axcan Pharma Inc.
  • MORE

Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting. Chemotherapy Induced Nausea and Vomiting - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Nausea and Vomiting.
- READ MORE >

FEATURED COMPANIES

  • A.P. Pharma, Inc.
  • Acacia Pharma Ltd.
  • AGI Therapeutics plc
  • Almac Discovery Ltd.
  • Aphios Corporation
  • Axcan Pharma Inc.
  • MORE

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Chemotherapy Induced Nausea and Vomiting Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Chemotherapy Induced Nausea and Vomiting 11
Chemotherapy Induced Nausea and Vomiting Therapeutics under Development by Companies 13
Chemotherapy Induced Nausea and Vomiting Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Chemotherapy Induced Nausea and Vomiting Therapeutics – Products under Development by Companies 22
Chemotherapy Induced Nausea and Vomiting Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Chemotherapy Induced Nausea and Vomiting Therapeutics Development 25
BioDelivery Sciences International, Inc. 25
Merck & Co., Inc. 26
A.P. Pharma, Inc. 27
Aphios Corporation 28
Axcan Pharma Inc. 29
Dr. Reddy's Laboratories Limited 30
IntelGenx Technologies Corp. 31
ProStrakan Group plc 32
AGI Therapeutics plc 33
Teikoku Pharma USA, Inc. 34
SymBio Pharmaceuticals Limited 35
INSYS Therapeutics, Inc. 36
Helsinn Healthcare S.A. 37
Shin Nippon Biomedical Laboratories, Ltd. 38
Almac Discovery Ltd. 39
Acacia Pharma Ltd. 40
Chemotherapy Induced Nausea and Vomiting – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
rolapitant hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ondansetron MR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
granisetron - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dronabinol Nanoformulation - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
granisetron - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
granisetron - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ondansetron CR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
arbaclofen - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
granisetron - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
aprepitant - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Aprepitant + Ramosetron + Dexamethasone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MK-0869 + MK-0517 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Granisetron + Dexamethasone - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Ramosetron + Aprepitant + Dexamethasone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Zindol - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
droperidol - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Emend + Kevatril + Dexamethasone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
aprepitant - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Aprepitant + Palonosetron + Dexamethasone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
TPW-146 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
granisetron - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
netupitant + palonosetron hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Dexamethasone + Palonosetron - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Palonosetron + Dexamethasone + Aprepitant - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
APD-403 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Aprepitant + Palonosetron + Dexamethasone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Palonosetron + Ondansetron + Dexamethasone - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PF0713 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
EMEND + 5HT3 Receptor Antagonist + Dexamethasone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
aprepitant - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Palonosetron + Dexamethasone - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
granisetron - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
carbamazepine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
palonosetron hydrochloride New Formulation - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dronabinol Intavenous Solution - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
INT-0010 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Ondansetron + Dexamethasone + Aprepitant - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
amisulpride - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Chemotherapy Induced Nausea and Vomiting Therapeutics – Drug Profile Updates 90
Chemotherapy Induced Nausea and Vomiting Therapeutics – Discontinued Products 97
Chemotherapy Induced Nausea and Vomiting Therapeutics - Dormant Products 98
Chemotherapy Induced Nausea and Vomiting – Product Development Milestones 100
Featured News & Press Releases 100
Oct 16, 2012: A.P. Pharma Announces PDUFA Action Date For APF530 New Drug Application Resubmission 100
Sep 28, 2012: A.P. Pharma Resubmits New Drug Application For APF530 For Prevention Of Chemotherapy-Induced Nausea And Vomiting 100
Jul 10, 2012: A.P. Pharma Announces Allowance Of Three Patents Covering APF530 101
Jun 29, 2012: A.P. Pharma Announces Positive Phase III Study Data Of APF530 In Patients With Chemotherapy-Induced Nausea And Vomiting 101
Jun 29, 2012: GlaxoSmithKline Announces Label Changes To Zofran 102
Jun 22, 2012: Ono Pharma's Emend Capsule Receives Approval For Additional Indication For Pediatric Patients Aged 12 And Older 103
Jun 20, 2012: A.P. Pharma To Present APF530 Patient-Satisfaction Data From Phase III Study 103
May 31, 2012: A.P. Pharma Announces Publication Of Phase III Trial Results Of APF530 In ASCO 2012 Annual Meeting 104
Apr 26, 2012: ProStrakan's Sancuso Receives Marketing Authorization Approval in Europe 104
Apr 17, 2012: RedHill Announces Successful Pivotal Bioequivalence Trial With RHB-102 For Prevention Of Nausea And Vomiting In Cancer Patients 105
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 108
Disclaimer 108

List of Tables
Number of Products Under Development for Chemotherapy Induced Nausea and Vomiting, H2 2012 11
Products under Development for Chemotherapy Induced Nausea and Vomiting – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Development by Companies, H2 2012 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2012 24
BioDelivery Sciences International, Inc., H2 2012 25
Merck & Co., Inc., H2 2012 26
A.P. Pharma, Inc., H2 2012 27
Aphios Corporation, H2 2012 28
Axcan Pharma Inc., H2 2012 29
Dr. Reddy's Laboratories Limited, H2 2012 30
IntelGenx Technologies Corp., H2 2012 31
ProStrakan Group plc, H2 2012 32
AGI Therapeutics plc, H2 2012 33
Teikoku Pharma USA, Inc., H2 2012 34
SymBio Pharmaceuticals Limited, H2 2012 35
INSYS Therapeutics, Inc., H2 2012 36
Helsinn Healthcare S.A., H2 2012 37
Shin Nippon Biomedical Laboratories, Ltd., H2 2012 38
Almac Discovery Ltd., H2 2012 39
Acacia Pharma Ltd., H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 46
Chemotherapy Induced Nausea and Vomiting Therapeutics – Drug Profile Updates 90
Chemotherapy Induced Nausea and Vomiting Therapeutics – Discontinued Products 97
Chemotherapy Induced Nausea and Vomiting Therapeutics – Dormant Products 98
Chemotherapy Induced Nausea and Vomiting Therapeutics – Dormant Products (Contd..1) 99

List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2012 11
Products under Development for Chemotherapy Induced Nausea and Vomiting – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46

- BioDelivery Sciences International, Inc.
- Merck & Co., Inc.
- A.P. Pharma, Inc.
- Aphios Corporation
- Axcan Pharma Inc.
- Dr. Reddy's Laboratories Limited
- IntelGenx Technologies Corp.
- ProStrakan Group plc
- AGI Therapeutics plc
- Teikoku Pharma USA, Inc.
- SymBio Pharmaceuticals Limited
- INSYS Therapeutics, Inc.
- Helsinn Healthcare S.A.
- Shin Nippon Biomedical Laboratories, Ltd.
- Almac Discovery Ltd.
- Acacia Pharma Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos